Interleukin-18: Biology and role in the immunotherapy of cancer

S. Srivastava, N. Salim, M. J. Robertson

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Interleukin-18 (IL-18) is an immunostimulatory cytokine belonging to the IL-1 family. IL-18 can regulate both innate and adaptive immune responses through its effects on natural killer (NK) cells, monocytes, dendritic cells, T cells, and B cells. IL-18 acts synergistically with other pro-inflammatory cytokines to promote interferon-γ (IFN-γ) production by NK cells, T cells, and possibly other cell types. Systemic administration of IL-18 has been shown to have significant antitumor activity in several preclinical animal models. Phase I clinical trials of recombinant human IL-18 have demon- strated that it can be safely administered to patients with advanced cancer. Biologic effects of IL-18 therapy include acti- vation of monocytes, NK cells, and T cells and production of IFN-γ as well as other cytokines in vivo. A phase II study of IL-18 in patients with metastatic melanoma confirmed its safety but suggested limited efficacy of IL-18 monotherapy in this setting. IL-18 appears to act predominantly as a costimulatory cytokine and its optimal use for cancer immunotherapy may be in combination with other immunostimulatory cytokines, vaccines, or monoclonal antibodies.

Original languageEnglish (US)
Pages (from-to)3353-3357
Number of pages5
JournalCurrent Medicinal Chemistry
Volume17
Issue number29
DOIs
StatePublished - Jan 1 2010

Fingerprint

Interleukin-18
Immunotherapy
Neoplasms
T-cells
Cytokines
Natural Killer Cells
T-Lymphocytes
Interferons
Monocytes
Clinical Trials, Phase I
Adaptive Immunity
Interleukin-1
Innate Immunity
Dendritic Cells
Melanoma
Animals
B-Lymphocytes
Vaccines
Animal Models
Chemical activation

Keywords

  • Cytokine
  • Immunotherapy
  • Interferon-γ
  • Natural killer cell
  • Rituximab
  • T cell

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Interleukin-18 : Biology and role in the immunotherapy of cancer. / Srivastava, S.; Salim, N.; Robertson, M. J.

In: Current Medicinal Chemistry, Vol. 17, No. 29, 01.01.2010, p. 3353-3357.

Research output: Contribution to journalArticle

Srivastava, S. ; Salim, N. ; Robertson, M. J. / Interleukin-18 : Biology and role in the immunotherapy of cancer. In: Current Medicinal Chemistry. 2010 ; Vol. 17, No. 29. pp. 3353-3357.
@article{b9817b64f8b94fb28f42b3b34d23b88d,
title = "Interleukin-18: Biology and role in the immunotherapy of cancer",
abstract = "Interleukin-18 (IL-18) is an immunostimulatory cytokine belonging to the IL-1 family. IL-18 can regulate both innate and adaptive immune responses through its effects on natural killer (NK) cells, monocytes, dendritic cells, T cells, and B cells. IL-18 acts synergistically with other pro-inflammatory cytokines to promote interferon-γ (IFN-γ) production by NK cells, T cells, and possibly other cell types. Systemic administration of IL-18 has been shown to have significant antitumor activity in several preclinical animal models. Phase I clinical trials of recombinant human IL-18 have demon- strated that it can be safely administered to patients with advanced cancer. Biologic effects of IL-18 therapy include acti- vation of monocytes, NK cells, and T cells and production of IFN-γ as well as other cytokines in vivo. A phase II study of IL-18 in patients with metastatic melanoma confirmed its safety but suggested limited efficacy of IL-18 monotherapy in this setting. IL-18 appears to act predominantly as a costimulatory cytokine and its optimal use for cancer immunotherapy may be in combination with other immunostimulatory cytokines, vaccines, or monoclonal antibodies.",
keywords = "Cytokine, Immunotherapy, Interferon-γ, Natural killer cell, Rituximab, T cell",
author = "S. Srivastava and N. Salim and Robertson, {M. J.}",
year = "2010",
month = "1",
day = "1",
doi = "10.2174/092986710793176348",
language = "English (US)",
volume = "17",
pages = "3353--3357",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "29",

}

TY - JOUR

T1 - Interleukin-18

T2 - Biology and role in the immunotherapy of cancer

AU - Srivastava, S.

AU - Salim, N.

AU - Robertson, M. J.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Interleukin-18 (IL-18) is an immunostimulatory cytokine belonging to the IL-1 family. IL-18 can regulate both innate and adaptive immune responses through its effects on natural killer (NK) cells, monocytes, dendritic cells, T cells, and B cells. IL-18 acts synergistically with other pro-inflammatory cytokines to promote interferon-γ (IFN-γ) production by NK cells, T cells, and possibly other cell types. Systemic administration of IL-18 has been shown to have significant antitumor activity in several preclinical animal models. Phase I clinical trials of recombinant human IL-18 have demon- strated that it can be safely administered to patients with advanced cancer. Biologic effects of IL-18 therapy include acti- vation of monocytes, NK cells, and T cells and production of IFN-γ as well as other cytokines in vivo. A phase II study of IL-18 in patients with metastatic melanoma confirmed its safety but suggested limited efficacy of IL-18 monotherapy in this setting. IL-18 appears to act predominantly as a costimulatory cytokine and its optimal use for cancer immunotherapy may be in combination with other immunostimulatory cytokines, vaccines, or monoclonal antibodies.

AB - Interleukin-18 (IL-18) is an immunostimulatory cytokine belonging to the IL-1 family. IL-18 can regulate both innate and adaptive immune responses through its effects on natural killer (NK) cells, monocytes, dendritic cells, T cells, and B cells. IL-18 acts synergistically with other pro-inflammatory cytokines to promote interferon-γ (IFN-γ) production by NK cells, T cells, and possibly other cell types. Systemic administration of IL-18 has been shown to have significant antitumor activity in several preclinical animal models. Phase I clinical trials of recombinant human IL-18 have demon- strated that it can be safely administered to patients with advanced cancer. Biologic effects of IL-18 therapy include acti- vation of monocytes, NK cells, and T cells and production of IFN-γ as well as other cytokines in vivo. A phase II study of IL-18 in patients with metastatic melanoma confirmed its safety but suggested limited efficacy of IL-18 monotherapy in this setting. IL-18 appears to act predominantly as a costimulatory cytokine and its optimal use for cancer immunotherapy may be in combination with other immunostimulatory cytokines, vaccines, or monoclonal antibodies.

KW - Cytokine

KW - Immunotherapy

KW - Interferon-γ

KW - Natural killer cell

KW - Rituximab

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=77957945366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957945366&partnerID=8YFLogxK

U2 - 10.2174/092986710793176348

DO - 10.2174/092986710793176348

M3 - Article

C2 - 20712569

AN - SCOPUS:77957945366

VL - 17

SP - 3353

EP - 3357

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 29

ER -